Zobrazeno 1 - 10
of 41
pro vyhledávání: ''
Autor:
L. N. Mishchenko, O. V. Averkov
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 5, Pp 771-778 (2021)
Oral anticoagulant therapy is widely used in different patients for the prevention and treatment of thromboembolic events: in atrial fibrillation, deep vein thrombosis/pulmonary embolism, acute coronary syndrome, in the early postoperative period aft
Autor:
E. V. Filippov
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 16, Iss 6, Pp 1009-1016 (2020)
The article is devoted to topical issues of management of patients with pulmonary arterial hypertension and strategies for switching to riociguat therapy in patients with insufficient clinical response against the background of phosphodiesterase type
Autor:
N. M. Vorobyeva, Olga N. Tkacheva
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 16, Iss 6, Pp 984-993 (2020)
The administration of oral anticoagulants in elderly patients with geriatric syndromes such as senile asthenia syndrome, falls and high risk of falls, dementia, polymorbidity, polypharmacy are discussed in the article. The evidence base for the antic
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 16, Iss 6, Pp 1002-1008 (2020)
After suffering pulmonary embolism (PE), doctors are confronted with various consequences of the disease, from asymptomatic residual pulmonary thrombosis to the formation of chronic thromboembolic pulmonary hypertension (CTEPH). There is also a subgr
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 16, Iss 4, Pp 528-535 (2020)
The high prevalence of lipid metabolism disorders in the Russian population and their contribution to cardiovascular risk require an optimization of their pharmacotherapy in clinical practice.Aim. To study the possible benefits of statin therapy in f
Autor:
G P Arutyunov, Marina Vladimirovna Shestakova, I. G. Gordeyev, Victor S. Gurevich, Yu. A. Karpov, Marat V. Ezhov, Kukharchuk Vv, E I Tarlovskaya, S. A. Urazgildeyeva, M. I. Voyevoda, M. G Bubnova, Yu. Sh. Khalimov, N. M. Akhmedzhanov, Oxana Drapkina, E. M. Nifontov, S. A. Sayganov, S. V. Nedogoda, I. V. Sergiyenko, A. S. Aliyeva, V V Skibitskiy, V. O. Konstantinov, А. S. Galyavich, Ya A Orlova, A. V. Panov, A I Martynov, Sergey Boytsov
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 15, Iss 2, Pp 282-288 (2019)
Tactics for the management of patients with hypertriglyceridemia (HTG) is provided in the conclusion of the Advisory Board. It is demonstrated that HTG is quite prevalent in patients with excessive body weight and is an important component of residua
Autor:
M. V. Derevyanchenko, M. E. Statsenko
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 14, Iss 2, Pp 217-222 (2018)
Aim. To study the effect of long-term combined antihypertensive therapy with lisinopril plus amlodipine on the parameters of central aortic pressure (CAD) and visceral obesity in patients with arterial hypertension (HT) combined with type 2 diabetes
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 14, Iss 2, Pp 190-196 (2018)
Aim. To study the effectiveness of achievement of lipid profile target levels and safety of therapy with atorvastatin in different doses in patients with acute ST-segment elevation myocardial infarction (STEMI).Material and methods. The open prospect
Autor:
R. M. Bogieva, I V Zhirov, S. N. Nasonova, M. A. Saidova, Tereshchenko Sn, T. M. Uskach, M. V. Lediakhova, V P Masenko, M. V. Andreevskaya
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 14, Iss 2, Pp 176-183 (2018)
Background. Levosimendan infusion can be used in the treatment of patients with acute decompensated heart failure (ADHF) with a reduction in cardiac output and signs of severe congestion/pulmonary edema.Aim. To study impact of levosimendan on renal f
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 13, Iss 5, Pp 716-724 (2017)
The opinion is expressed in some domestic publications that rivaroxaban has the most favorable profile of drug interaction in comparison with other new oral anticoagulants (NOAC). The basis for such judgments is the summary table of drug interaction